BioStem Technologies is a buy due to strong YoY growth, profitability, and undervaluation versus sector peers despite recent Q1 misses. Their advanced wound care products, powered by proprietary BioREtain technology, address a growing chronic wound market fueled by aging and diabetes trends. Balance sheet strength is notable, with assets outpacing liabilities and a rising cash position, supporting ongoing expansion and innovation.
Upon SEC approval of the amended Form 10, BioStem expects to advance its uplisting to Nasdaq POMPANO BEACH, Fla., June 3, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
POMPANO BEACH, Fla., May 29, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami.
Expanding patent portfolio reinforces the Company's commitment to wound care innovation, with 55 issued patents and 52 pending applications POMPANO BEACH, Fla., May 28, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future POMPANO BEACH, Fla., May 22, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies, Inc. (OTCPK:BSEM) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Adam Holdsworth - Director-Investor Relations Jason Matuszewski - Chief Executive Officer Mike Fortunato - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Erik Voss - Mission Vertical Operator Thank you for standing by. My name is Stan and I'll be your conference operator today.
POMPANO BEACH, FL, May 12, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today reported preliminary financial results for the first quarter ended March 31, 2025.
Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three accepted scientific posters will feature BioStem's advanced allograft portfolio POMPANO BEACH, Fla., May 1, 2025 – PRiSM MediaWire – BioStem Technologies, Inc.
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 30, 2025 – PRISM MediaWire – BioStem Technologies Inc.
The presentation will be webcast at 10:30 AM ET on April 22, 2025 POMPANO BEACH, Fla., April 21, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies, Inc. (OTCPK:BSEM) Q4 2024 Earnings Conference Call April 14, 2025 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executive Officer Michael Fortunato - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Erik Voss - Mission Vertical Mitchell Sacks - Grand Slam Richard Huebner - GVC Capital Operator Please stand by.
Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 08, 2025 – PRISM MediaWire – BioStem Technologies Inc.